Armed with Deep Expertise in Immunology, We Are Up to
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, virus-like particles (VLPs) are ideal for stimulating potent immune responses. Most of the emerging and re-emerging viruses that pose significant health threats are enveloped viruses, making them a prime target for VBI’s proprietary enveloped virus-like particle (eVLP) platform technology.
VBI is a global biopharmaceutical company, with corporate headquarters in Cambridge, MA, United States, research and development facilities in Ottawa, Canada, and a research and manufacturing facility in
Our team includes leaders and advisors with extensive immunology, vaccine development, medical, commercial, and industry expertise.
For us, this fight is personal, and we all share an unyielding determination to bring innovation to the prevention and treatment
At VBI, we believe that it takes the power of many great minds and organizations to solve the toughest challenges.
We value our partnerships with teams that share our philosophy and vision, and continue to seek meaningful collaborations across industry, government, and
